SCHEMBL4352949

SCHEMBL4352949

NC(=O)c1ccc(S(=O)(=O)NC2CCCCC2)c2c1CCCC2

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
LMNA P02545 3/20 0.44
MCOLN3 Q8TDD5 1/20 0.44
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 1/20 0.43
RECQL P46063 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CCR8 P51685 1/20 0.43
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4352952 0.81 ALDH1A1 (0.48) ALDH1A1LMNAMCOLN3GAAHTT
SCHEMBL1339749 0.80 CCR8 (0.52) ALDH1A1HTTCCR8MAPTL3MBTL1
SCHEMBL4343028 0.79 GAA (0.64) ALDH1A1GAAHTTNPSR1KDM4E
SCHEMBL27768339 0.78 ALDH1A1 (0.57) ALDH1A1LMNAMCOLN3GAAHTT
SCHEMBL1337354 0.76 CCR8 (0.51) ALDH1A1LMNAMCOLN3GAAHTT
SCHEMBL919063 0.74 HSD17B10 (0.46) ALDH1A1HTTKDM4EMEN1KMT2A
SCHEMBL35972 0.74 HSD17B10 (0.46) ALDH1A1HTTKDM4EMEN1KMT2A
SCHEMBL8708889 0.74 HSD17B10 (0.46) ALDH1A1HTTKDM4EMEN1KMT2A
SCHEMBL35787 0.74 HSD17B10 (0.46) ALDH1A1HTTKDM4EMEN1KMT2A
SCHEMBL16739249 0.74 HSD17B10 (0.46) ALDH1A1HTTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275556-A1 Aryl sulfonamides useful as inhibitors of chemokine receptor activity MILLENNIUM PHARMACEUTICALS, INC. 2009-11-05 US disclosed
US-7491827-B2 Aryl sulfonamides useful as inhibitors of chemokine receptor activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-02-17 US disclosed
US-7378525-B2 CCR8 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-05-27 US disclosed
US-7329755-B2 especially naphthalene sulfonamides, used for treating asthma MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-02-12 US disclosed
EP-1590327-A1 CCR8 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-02 EP disclosed
EP-1581511-A1 CCR8 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-10-05 EP disclosed
US-20050085518-A1 Aryl sulfonamides useful as inhibitors of chemokine receptor activity MILLENNIUM PHARMACEUTICALS, INC. 2005-04-21 US disclosed
US-20040224978-A1 CCR8 inhibitors MILLENNIUM PHARMACEUTICALS, INC. 2004-11-11 US disclosed
US-20040209948-A1 CCR8 Inhibitors MILLENNIUM PHARMACEUTICALS, INC. 2004-10-21 US disclosed
WO-2004058709-A1 CCR8 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2004-07-15 WO disclosed
WO-2004058736-A1 CCR8 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085518-A1 Aryl sulfonamides useful as inhibitors of chemokine receptor activity CCR8, CCR1, CCR3 ALDH1A1 1041/4885LMNA 4775/4885MCOLN3 3246/4885
US-20090275556-A1 Aryl sulfonamides useful as inhibitors of chemokine receptor activity CCR8, CCR1, CCR3 ALDH1A1 760/4885LMNA 4779/4885MCOLN3 3369/4885
US-20040209948-A1 CCR8 Inhibitors CCR8, CCR1, CCR3 ALDH1A1 498/4885LMNA 4157/4885MCOLN3 2259/4885
US-20040224978-A1 CCR8 inhibitors CCR8, CCR1, CCRL2 ALDH1A1 491/4885LMNA 3961/4885MCOLN3 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.